GLP-1RAs prolong recurrence-free and overall survival post-HCC resection in type 2 diabetes.
Background
Recurrence of hepatocellular carcinoma (HCC) after curative resection remains a significant challenge, particularly in patients with co-existing type 2 diabetes (T2D). Current standard-of-care often falls short in preventing recurrence in this high-risk population. While incretin-based therapies like GLP-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4is) are widely used for T2D management, their comparative impact on postoperative outcomes, specifically HCC recurrence and survival, has been unclear. This study addresses this critical knowledge gap.
Study Design
Researchers conducted an active-comparator, new-user target trial emulation study using electronic medical records from 36 hospitals across China (2014-2023). The cohort included adults with histologically confirmed HCC and T2D who underwent R0 resection and initiated either a GLP-1RA or DPP-4i within 0 to 90 postoperative days. Time zero was the first qualifying prescription. The primary endpoint was recurrence-free survival (RFS), with death without recurrence treated as a competing event. Overall survival (OS) was a secondary outcome. A prespecified per-protocol analysis assessed sustained adherence.
Results
Among 42,855 patients with HCC and T2D who underwent liver resection, 1249 were included in the final analytical cohort, comprising 723 DPP-4i initiators and 526 GLP-1RA initiators, with a median follow-up of 50.8 months. In weighted intention-to-treat analyses, initiation of GLP-1RAs, compared to DPP-4is, demonstrated significant improvements in both recurrence-free and overall survival. The cause-specific hazard ratio for RFS was 0.80 (95% CI 0.67 to 0.96; p=0.016), indicating a 20% reduction in recurrence risk. Per-protocol analyses consistently supported these findings.
GLP-1RA initiation was associated with a substantial improvement in overall survival, with a hazard ratio of 0.58 (95% CI 0.47 to 0.71; p<0.001), representing a 42% reduction in mortality risk.
Key Findings
- GLP-1RA initiation was associated with longer recurrence-free survival (RFS) compared to DPP-4is.
- GLP-1RAs reduced the risk of HCC recurrence by 20% (HR 0.80, p=0.016) in T2D patients post-resection.
- GLP-1RA initiation significantly improved overall survival (OS) compared to DPP-4is.
- GLP-1RAs reduced the risk of mortality by 42% (HR 0.58, p<0.001) in this patient cohort.
- Per-protocol analyses were directionally consistent with intention-to-treat results.
Why It Matters
This study provides compelling real-world evidence suggesting that GLP-1RAs may offer significant survival benefits over DPP-4is for T2D patients undergoing HCC resection. For clinicians managing T2D in this specific patient population, this finding could influence postoperative pharmacological choices, potentially shifting towards GLP-1RAs as an adjuvant therapy to improve long-term outcomes. While not a direct protocol, it highlights the potential for GLP-1RAs to play a role beyond glycemic control in oncology. Further prospective studies are needed to solidify these findings and potentially integrate GLP-1RAs into future adjuvant treatment guidelines for HCC.
glp-1ra
dpp-4i
hcc
type-2-diabetes
liver-resection
recurrence